nivolumab   

GtoPdb Ligand ID: 7335

Synonyms: BMS-936558 | MDX-1106 | ONO-4538 | Opdivo®
nivolumab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Nivolumab is an IgG4 kappa immunoglobulin that is selective for PD-1, an immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells [12]. This monoclonal is produced in Chinese hamster ovary cells by recombinant DNA technology. Nivolumab is an immuno-oncology drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Sequence analysis of the light and heavy chain variable region peptides of nivolumab shows exact matches with claimed peptide sequences of monoclonal 5C4 contained in patent WO2006121168 [10].
Immunopharmacology Comments
Nivolumab is an immuno-oncology drug, targeting various cancers via blockade of the PD-1 immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells [12]. Checkpoint inhibition is a mechanism of action now widely accepted as efficacious for cancer immunotherapy [16,19].
Immunopharmacology Disease
Disease X-Refs Comment References
Lymphoma, Hodgkin, Classic; CHL Disease Ontology: DOID:8567
OMIM: 236000
Approved drug for cHL.
Renal cell carcinoma Disease Ontology: DOID:4450
A combination therapy of nivolumab plus ipilimumab was granted FDA approval in April 2018 , for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma 2,14